-
1 week ago | 
pharmacytimes.com | Alexandra Gerlach |Zahra Mahmoudjafari
In an interview with Pharmacy Times at the HOPA Annual Meeting 2025, Zahra Mahmoudjafari, PharmD, BCOP, FHOPA, clinical pharmacy manager at the University of Kansas Cancer Center, highlighted the annual conference's benefits, including educational sessions on hematology and oncology, advocacy updates, and professional development opportunities. Pharmacy Times: Can you introduce yourself? What is your relationship with HOPA? Zahra Mahmoudjafari, PharmD, BCOP, FHOPA: My name is Zahra Mahmoudjafari.
-
2 weeks ago | 
pharmacytimes.com | Luke Halpern |Kennedy Ferruggia |Zahra Mahmoudjafari
CommentaryVideoApril 8, 2025Author(s):,Pharmacists are essential navigators in the complex landscape of gene therapy. In an interview with Pharmacy Times, Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, clinical pharmacy manager in the Blood and Marrow Transplant Program in the Division of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Cancer Center in Kansas City, Kansas, discussed how gene therapy treatments represent a complex and evolving field.
-
1 month ago | 
nature.com | James Davis |Mikhaila Rice |Kelley Julian |Charlotte Wagner |Shebli Atrash |Jack Khouri | +1 more
TO THE EDITOR:Cytokine release syndrome (CRS) is a systemic inflammatory response triggered by the activation of T-cells and is commonly seen in patients receiving immune effector cell therapies such as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies (BsAbs) which target varying tumor antigens such as CD19, CD20, B-cell maturation antigen (BCMA), or GPRC5D depending on the type of malignancy.
-
2 months ago | 
cancernetwork.com | Al-Ola Abdallah |Muhammad Umair Mushtaq |Jeries Kort |Zahra Mahmoudjafari
January 31, 2025By Panelists discuss how expanding CAR T therapy into earlier lines of multiple myeloma treatment requires careful evaluation of clinical trial data, infrastructure readiness, patient selection criteria, and manufacturing capacity while balancing the therapy’s potential benefits against established treatment approaches.
-
2 months ago | 
cancernetwork.com | Al-Ola Abdallah |Muhammad Umair Mushtaq |Jeries Kort |Zahra Mahmoudjafari
January 31, 2025By Panelists discuss how successful comanagement of CAR T-cell therapy cases requires close coordination between academic centers and community practices, with structured protocols for monitoring, communication, and patient handoffs, while addressing challenges in referral timing, resource allocation, and long-term follow-up care.
-
Jan 24, 2025 | 
cancernetwork.com | Al-Ola Abdallah |Muhammad Umair Mushtaq |Jeries Kort |Zahra Mahmoudjafari
January 24, 2025By Panelists discuss how CAR T-cell therapy, a groundbreaking immunotherapy treatment, works by extracting a patient’s T cells, genetically modifying them to target cancer cells, and reinfusing them back into the patient’s body through a process that involves close monitoring and specialized careVideo content above is prompted by the following:Could you explain how CAR T-cell therapy works and describe the treatment process at University of Kansas Medical Center?
-
Jan 24, 2025 | 
cancernetwork.com | Al-Ola Abdallah |Muhammad Umair Mushtaq |Jeries Kort |Zahra Mahmoudjafari
January 24, 2025By Panelists discuss how bridging therapy during the CAR T manufacturing waiting period requires careful patient-specific decisions about whether to use chemotherapy, targeted agents, or observation alone, based on disease aggressiveness, patient condition, and expected manufacturing timeframes. Video content above is prompted by the following:Can you explain your institution’s approach to bridging therapy for patients awaiting CAR T-cell manufacturing and infusion?
-
Jan 20, 2025 | 
cancernetwork.com | Al-Ola Abdallah |Muhammad Umair Mushtaq |Jeries Kort |Zahra Mahmoudjafari
January 20, 2025By Panelists discuss how the chimeric antigen receptor T-cell referral pathway progresses from initial community physician contact through patient evaluation and final selection, highlighting the key steps and considerations in the institutional workflow process.
-
Jan 10, 2025 | 
cancernetwork.com | Al-Ola Abdallah |Muhammad Umair Mushtaq |Jeries Kort |Zahra Mahmoudjafari
January 10, 2025By Panelists discuss how patient selection criteria for second-line chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma encompass both clinical eligibility guidelines and practical considerations, including geographical and financial factors.
-
Jan 6, 2025 | 
cancernetwork.com | Al-Ola Abdallah |Muhammad Umair Mushtaq |Zahra Mahmoudjafari |Jeries Kort
January 3, 2025By Panelists discuss how institutional challenges around chimeric antigen receptor T-cell therapy slot availability and waiting list management influence treatment sequencing decisions and affect subsequent therapy choices in earlier treatment lines for multiple myeloma.
